Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Solid Tumors, Adult 1Recurrence 1Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Diarrhea 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Breast Neoplasms 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × Drugs, Investigational × Clear all
NCT05972720 2025-05-15

FIRCE-1

CARGO Therapeutics

Phase 2 Terminated
101 enrolled
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡